![Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37]](https://cedclinic.com/wp-content/uploads/2026/07/ced-pexels-5021600-150x150.jpg "Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37] 19")
Policy Watch: 20 Regulatory Updates — April 25, 2026
Policy WatchApril 25, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal Register Schedules…
Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine in Schedule I
The DEA drug scheduling updates include placing 3-methoxyphencyclidine in Schedule I due to its high abuse potential. This synthetic phencyclidine analog lacks accepted medical use. Understanding these updates helps clinicians anticipate regulatory…
CED Regulatory Digest, Since Last Digest, 2 items
Digest covering 2 recent regulatory items.
Policy Watch: 10 Regulatory Updates — March 19, 2026
This update covers DEA synthetic opioid scheduling and regulatory changes relevant to cannabis clinicians. The focus is on new Schedule I placements and their clinical implications. These regulatory updates inform patient care and research considerations.
Policy Watch: 26 Regulatory Updates — March 08, 2026
The marijuana rescheduling proposal is a key focus in the March 2026 regulatory updates. This change could impact cannabis clinical practice and research access. Marijuana rescheduling remains central to evolving federal cannabis policy.